Observational studyBMC infectious diseases2026
Epidemiology of tick-borne diseases diagnosed in patients in north-eastern Italy, 2015-2022.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundIxodes ricinus is the most abundant tick species in Europe and a primary vector for multiple pathogens affecting human and animal health. Over the past 70 years in Europe, including Italy, the geographical distribution of I. ricinus has expanded, increasing the opportunities for tick-human interactions. This observational retrospective study evaluates tick-borne disease (TBD) diagnostic activities conducted from 2015 to 2022 in northeastern Italian hospitals, focusing on areas with significant I. ricinus presence.
methodsData from over 49,000 human samples that underwent serological screening for Lyme borreliosis (LB), rickettsiosis, anaplasmosis, babesiosis, and tick-borne encephalitis (TBE) were extracted from the information systems of the 4 participating hospitals.
resultsOver 52,000 individual serological tests on this population with suspected TBD were performed, primarily for LB (78.4%) and TBE (16.7%), with positivity rates of 14.8% and 21%, respectively, showing significant increasing trend between 2015 and 2022. Male patients predominated (51% for LB and 61% for TBE), especially for IgG positivity, with the 60-69 (LB) and 40-49 (TBE) age groups most affected. Rickettsiosis testing revealed 11.5% positivity with a stable trend, affecting both genders equally, predominately in the 30-39 age group. Anaplasmosis diagnostics (248 tests) showed a maximum positivity rate of ~ 9%, while limited babesiosis testing (64 tests) indicated up to 50% positivity in recent years.
conclusionsThe findings underscore the need for enhanced diagnostic tests, vigilant surveillance, and ongoing public education on TBD risks as crucial strategies to mitigate infection risk and reduce the public health impact of TBDs in the northeastern of Italy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.